Price
6.32
+13.26%52W Range
Market Cap
₹16.61 Cr
Traded: ₹0.08 Cr (0.50%) 0.0x
Free Float: ₹7.38 Cr (1.13% of FF traded)
Volume · 60D trend
1.35 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +5.0% | +4.0% | -- | -- | Decelerating |
| Sales | -- | +33.0% | +20.0% | -- | -40.0% | Decelerating |
| Profit | -- | +74.0% | -6.0% | -- | +147.0% | Stable |
| Return | -- | -- | -20.0% | -69.0% | -- | Decelerating |
Quarterly Results
Mar 2022
Sep 2021
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Sep 2025PDF ↗ | Mar 2025PDF ↗ | Sep 2024PDF ↗ | Mar 2024PDF ↗ | Sep 2023PDF ↗ | Mar 2023PDF ↗ | Sep 2022PDF ↗ | Mar 2022 | Sep 2021 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 74 | 34 | 91 | 90 | 74 | 74 | 49 | 44 | 29 |
| Expenses | 71 | 32 | 89 | 88 | 73 | 73 | 48 | 42 | 28 |
| Operating Profit | 3 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | 1 |
| OPM % | 4.0% | 6.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | 3.0% | 3.0% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| Tax % | 26.0% | 34.0% | 26.0% | 21.0% | 27.0% | 27.0% | 26.0% | 26.0% | 25.0% |
| Net Profit | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 0.6 | 0.3 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 84.0 | 33.0 |
| Sales Growth (YoY) | -18.7% | -62.2% | 23.0% | 21.6% | 51.0% | 68.2% | 69.0% | -- | -- |
| Sales Growth (QoQ) | 117.7% | -62.6% | 1.1% | 21.6% | 0.0% | 51.0% | 11.4% | 51.7% | -- |
| OP Growth (YoY) | 200.0% | 0.0% | -50.0% | 0.0% | 100.0% | 100.0% | 0.0% | -- | -- |
| OP Growth (QoQ) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Profit Growth (YoY) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | 321.4% | 35.0% | -41.7% | -16.7% | 84.6% | -99.7% | -99.6% | -- | -- |
| EPS Growth (QoQ) | 118.5% | 92.9% | -30.0% | -16.7% | 0.0% | 84.6% | -99.8% | 154.6% | -- |
| OP Margin | 4.0% | 5.9% | 1.1% | 2.2% | 2.7% | 2.7% | 2.0% | 2.3% | 3.5% |
| Net Margin | 1.4% | 2.9% | 0.0% | 0.0% | 1.4% | 1.4% | 0.0% | 2.3% | 0.0% |
| Material Cost % | 85.0% | 77.0% | 97.0% | 96.0% | 96.0% | 96.0% | 96.0% | 94.0% | 95.0% |
| Employee Cost % | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 1.0% |
| P/S | 0.15 | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 7.35 | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.28 | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Announcement under Regulation 30 (LODR) - Newspaper Publication
Submission of Statment of Deviation and Variation
Submission of Integrated Financials
Submission of Financial Results
Outcome of Board Meeting held today i.e. 2nd July, 2026
Announcement under Regulation 30 (LODR) - Resignation of Director
Announcement under Regulation 30 (LODR) - Resignation of Director
Announcement under Regulation 30 (LODR) - Change in Directorate
Outcome and Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Outcome and Intimation for Rescheduling of Board Meeting to 2nd July, 2026
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2026 ,inter alia, to consider and approve Outcome and Intimation for ....
Intimation of Closure of Trading Window
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/07/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....
Annual Secretarial Compliance Report under Reg. 24(A) of SEBI (LODR) Regulations, 2015 for the year ended on 31st March, 2026
Voting Results for Postal Ballot
Post Ballot - Scrutinizer''s Report
Announcement under Regulation 30 (LODR)- Newspaper Publication
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Notice of Postal Ballot
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Outcome of the Board meeting and Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Compliances - Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Clarification sought on significant movement in price
Intimation of Closure of Trading Window
The Exchange has sought clarification from Dipna Pharmachem Ltd on February 23, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Intimation of Trading approval received for 22,44,000/- equity shares.
Clarification Sought on significant movement in price
The Exchange has sought clarification from Dipna Pharmachem Ltd on January 13, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Submission of Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for Quarter ended on 31st December, 2025
Board of Directors, at its meeting held on today, consider and allotted 22,44,000 Equity Shares pursuant to the conversion of warrants the 22,44,000 convertible warrants (out of a total ....
Allotment of 22,44,000 Equity Shares pursuant to the conversion of 22,44,000 convertible warrants ( Out of a total 5,80,32,500 Convertible warrants) to the allottee(s) belonging to the ....
Outcome of Board Meeting held today i.e. Wednesday, 26th November, 2025
Statement of Deviation and Variation
Integrated Fillig(Finance)
Unaudited Financial Results For the Half year ended on 30th September, 2025.
Announcement under Regulation 30 (LODR) - Resignation of Director
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/11/2025 ,inter alia, to consider and approve Pursuant to Regulation 29(1) ....
Dipna Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Intimation of Board Meeting ....
Compliances certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Intimation of Closure of Trading Window
Outcome of Board Meeting
Allotment of 2,98,74,000 Convertible Warrants pursuant to the preferential issue.
Voting Results of the Annual General Meeting held on 30th August, 2025.
Scrutinizer Report of the Annual General Meeting held on 30th August, 2025.
Outcome and Summary of the 14th Annual General Meeting held on 30th August, 2025.
Intimation of In-principle approval in matter of issue of 7,66,05,000 warrants convertible into equity shares on preferential basis received from BSE is attached herewith.
Undertaking regarding Appointment of Monitoring Agency in matter of Preferential issue of Equity Shares of the Company
Intimation of Book Closure
Outcome of Board Meeting held on 8th August, 2025
Annual Report for Financial Year 2024-25
Intimation of Annual General Meeting to be held on 30th August, 2025